RG 7716

Drug Profile

RG 7716

Alternative Names: RG-7716; RO-6867461

Latest Information Update: 08 Feb 2017

Price : $50

At a glance

  • Originator Roche
  • Class Bispecific antibodies; Eye disorder therapies
  • Mechanism of Action Angiopoietin-2 modulators; Vascular endothelial growth factor A modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diabetic macular oedema; Wet age-related macular degeneration

Most Recent Events

  • 01 Jan 2017 Phase-II clinical trials in Wet age-related macular degeneration (Monotherapy, Treatment-naive) in USA (Intravitreous) (NCT03038880)
  • 01 Mar 2016 Phase-II clinical trials in Diabetic macular oedema in USA (Intravitreous) (NCT02699450)
  • 01 Mar 2016 Roche plans a phase II trial for Diabetic Macular Oedema in USA (NCT02699450)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top